A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/jco.2009.27.18s.lba4PMID 27937593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment

  2023cites this paper
• Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

  2018cites this paper
• HMGA2 promotes vasculogenic mimicry and tumor aggressiveness by upregulating Twist1 in gastric carcinoma

  2017cites this paper
• Targeting metastasis

  2016cites this paper
• Prognostic impact of mutation profiling in patients with stage II and III colon cancer

  2016cites this paper
• Modélisation de données pharmacologiques précliniques et cliniques d'efficacité des médicaments anti-angiogéniques en cancérologie. (Modeling of preclinical and clinical pharmacological data for the efficacy of antiangiogenic compounds in oncology)

  2016cites this paper
• Ten years of anti-vascular endothelial growth factor therapy

  2016cites this paper
• Influence of vascular normalization on interstitial flow and delivery of liposomes in tumors

  2015cites this paper
• Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings

  2015cites this paper
• 1+1=? Combinations and combination strategies in early cancer-drug development

  2014cites this paper
• The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer

  2013cites this paper
• Differential Therapeutic Effects of Anti–VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing

  2013cites this paper
• Advanced colorectal cancer: Exploring treatment boundaries

  2013cites this paper
• SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

  2013cites this paper
• Potential Novel Drugs to Combine with Radiation in Rectal Cancer

  2012cites this paper
• The Current State of Targeted Agents in Rectal Cancer

  2012cites this paper
• An update on chemotherapy of colorectal liver metastases.

  2012cites this paper
• The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

  2012cites this paper
• Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

  2012cites this paper
• Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer

  2012cites this paper
• Therapeutic Kinase Inhibitors

  2012cites this paper
• Adjuvant therapy in colon cancer

  2012cites this paper
• Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program

  2012cites this paper
• Neue Forschungsergebnisse zum Kolonkarzinom, Magenkarzinom, Sarkomen und Bronchialkarzinom

  2011cites this paper
• Biotherapy in the Adjuvant Treatment of Colorectal Cancer

  2011cites this paper
• Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

  2011cites this paper
• Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.

  2011cites this paper
• Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Gastrointestinale Tumore – interdisziplinäre Diskussion neuer Daten

  2011cites this paper
• Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

  2011cites this paper
• Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

  2011cites this paper
• Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer.

  2011cites this paper
• The role of bevacizumab in colorectal cancer: understanding its benefits and limitations

  2011cites this paper
• Kolonkarzinom: Aktueller Stand der multimodalen Therapie

  2011cites this paper
• Vascular endothelial growth factor inhibition: conflicting roles in tumor growth.

  2011cites this paper
• The Role of Chemotherapy in Managing Patients With Resectable Liver Metastases

  2010cites this paper
• Angiogenesis inhibitors in the management of breast cancer

  2010cites this paper
• Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology

  2010cites this paper
• Improving response and outcomes for patients with liver-limited metastatic colorectal cancer.

  2010cites this paper
• Antiangiogenic therapies in early-stage breast cancer.

  2010cites this paper
• Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

  2010influential citation
• Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future

  2010cites this paper
• Antiangiogenic therapy in colorectal cancer: where are we 5 years later?

  2010cites this paper
• Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

  2010cites this paper
• Colon cancer.

  2010influential citation
• Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects

  2010cites this paper
• Targeted therapeutic agents for colorectal cancer.

  2010cites this paper
• Trastuzumab in gastric cancer.

  2010cites this paper
• Adjuvant and neoadjuvant therapy in colorectal cancer

  2010cites this paper
• Current progress in targeted therapy for colorectal cancer.

  2010cites this paper
• Bevacizumab: current updates in treatment

  2010cites this paper
• It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor–vascular endothelial growth factor receptor pathway in patients with solid malignancies

  2010cites this paper
• Treatment of Liver-Limited Metastatic Colorectal Cancer

  2010cites this paper
• Stage II and Stage III Colon Cancer: Treatment Advances and Future Directions

  2010cites this paper
• Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis

  2010cites this paper
• Targeting angiogenesis in melanoma: prospects for the future

  2010cites this paper
• Nasopharyngeal carcinoma: the next challenges.

  2010cites this paper
• Adjuvant Therapy in Colon Cancer

  2010cites this paper
• Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents

  2010cites this paper
• Surgical Treatment of Colorectal Cancer. Controversial Issues

  2010cites this paper
• Traitement adjuvant du cancer colique : quelles pistes après MOSAIC ?

  2010cites this paper
• Antiangiogenesis agents in colorectal cancer

  2010cites this paper
• A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.

  2010cites this paper
• Medikamentöse Therapie des kolorektalen Karzinoms

  2010cites this paper
• Palliative Chemotherapie beim kolorektalen Karzinom – Stand, Wertigkeit, Tendenzen

  2010cites this paper
• Anti-angiogenesis therapies: their potential in cancer management

  2010cites this paper
• [Chemotherapy for colorectal cancer].

  2009cites this paper
• Maintenance Capecitabine for High-Risk Gastrointestinal Tumors: Everything That's Old Is New Again.

  2009cites this paper
• Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

  2009cites this paper
• Raltitrexed: optimism and reality

  2009cites this paper
• VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation

  2009cites this paper
• Adjuvante Therapie des Kolonkarzinoms

  2009cites this paper
• Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.

  2009cites this paper
• Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

  2009cites this paper
• Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

  2009cites this paper
• Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

  2009cites this paper
• Current status and future prospects for anti-angiogenic therapies in cancer

  2009cites this paper
• Metastatic colorectal cancer: recent advances in its clinical management

  2009cites this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Current Use and Potential Role of Bevacizumab in the Treatment of Gastrointestinal Cancers

  year unknowncites this paper